MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.
Also called NCT01847144
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 143 participants
- Sponsor
- Registry
-
NCT01847144
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01847144. Randomized; no masking; primary purpose basic science. Start 2013-04 (registry gives no type); primary completion 2015-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
- Acronym
- Mastermind
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Gliclazide 80mg OD
- Intervention (Drug)
- Sitagliptin 100mg OD
- Lead sponsor
- Royal Devon and Exeter NHS Foundation Trust
- Collaborator
- University of Exeter
Record details
- Record id
cardio:ct-nct01847144- Content hash
c29e814c20d91c889bc0b6a4c4016ed7f2fc636851a2cc288e7c9ed96261a0cc